Facebook Twitter YouTube Google Plus

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

Jason M. Foster, MD
University of Nebraska Medical Center

Jason M. Foster, M.D. received his medical degree from Temple University School of Medicine in Philadelphia, Pennsylvania and completed his general surgery residency at the University Hospitals of Cleveland/Case Western Reserve in Cleveland, Ohio. Dr. Foster is a SSO trained surgical oncologist who treats a broad range of malignant diseases including cancer of the gastrointestinal tract; endocrine organs (pancreas, adrenal, thyroid, parathyroid), soft tissue sarcomas (extremities, retroperitoneum and abdomen), skin tumors (melanoma, merkel cell, squamous cell, etc.) and peritoneal based malignancies.  Dr. Foster’s additional interests include the use of minimally invasive surgery in oncology and the use of hyperthermic therapies including radiofrequency ablation of tumors, isolated limb perfusions/infusions (ILP/ILI) and intraperitoneal hyperthermic chemotherapy (IPHC).
He is also engaged in basic science/translational oncology research primarily focused on identification of the molecular pathways involved in tumors that present with peritoneal carcinomatosis and the development of novel therapeutics for these tumors.


Click here to view slides for "EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma", by Jason Foster, MD.

To view this video, please click on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion